Severe dyslipidemia and immune activation in HIV patients with dysglycemia

References

• Beltran S, Lescure FX, Desailloud R, Douadi Y, Smail A, Esper I, et al. Increased prevalence of hypothyroidism among human immunodeficiency virus--infected patients: A need for screening. Clin Infect Dis. 2003;37(4):579–583.10.1086/376626
   PubMed Web of Science ®Google Scholar
• McManus KA, Pinkerton R, Dillingham R. Effects of recent virginia AIDS drug assistance program policy changes on diabetes and hyperlipidemia control in people living with HIV. SAGE Open Med. 2014;2:2050312114532809.
   Google Scholar
• Friis-Moller N, Sabin CA, Weber R, d’Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;3499(21):1993–2003.
   Google Scholar
• Grunfeld C, Delaney JA, Wanke C, Currier JS, Scherzer R, Biggs ML, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS. 2009;23(14):1841–1849.10.1097/QAD.0b013e32832d3b85
   PubMed Web of Science ®Google Scholar
• Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506–2512.10.1210/jc.2006-2190
   PubMed Web of Science ®Google Scholar
• Sobieszczyk ME, Hoover DR, Anastos K, Mulligan K, Tan T, Shi Q, et al. Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the women’s interagency HIV study. J Acquir Immune Defic Syndr. 2008;48(3):272–280.10.1097/QAI.0b013e31817af461
   PubMed Web of Science ®Google Scholar
• Paruthi J, Gill N, Mantzoros CS. Adipokines in the HIV/HAART-associated lipodystrophy syndrome. Metabolism. 2013;62(9):1199–1205.10.1016/j.metabol.2013.04.014
   PubMed Web of Science ®Google Scholar
• Freitas P, Carvalho D, Santos AC, Madureira AJ, Martinez E, Pereira J, et al. Adipokines, hormones related to body composition, and insulin resistance in HIV fat redistribution syndrome. BMC Infect Dis. 2014;14:347.
   PubMed Web of Science ®Google Scholar
• Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165(10):1179–1184.10.1001/archinte.165.10.1179
   PubMedGoogle Scholar
• Estrada V, Geijo P, Fuentes-Ferrer M, Alcalde ML, Rodrigo M, Galindo MJ, et al. Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort. BMC Womens Health. 2011;11:36.10.1186/1472-6874-11-36
   PubMed Web of Science ®Google Scholar
• Adewole OO, Eze S, Betiku Y, Anteyi E, Wada I, Ajuwon Z, et al. Lipid profile in HIV/AIDS patients in Nigeria. Afr Health Sci. 2010;10(2):144–149.
   PubMed Web of Science ®Google Scholar
• De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, et al. Incidence and risk factors for new-onset diabetes in hiv-infected patients: The data collection on adverse events of Anti-HIV drugs (D:A:D) study. Diabetes Care. 2008;31(6):1224–1229.10.2337/dc07-2013
   PubMed Web of Science ®Google Scholar
• Zhang C, Chow FC, Han Y, Xie J, Qiu Z, Guo F, et al. Multicenter cohort study of diabetes mellitus and impaired fasting glucose in HIV-infected patients in China. J Acquir Immune Defic Syndr. 2015;68(3):298–303.10.1097/QAI.0000000000000474
   PubMed Web of Science ®Google Scholar
• Fan M, Li Y, Zhang S. Effects of Sitagliptin on Lipid Profiles in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Clinical Trials. Medicine (Baltimore). 2016;95(2):e2386.10.1097/MD.0000000000002386
   PubMed Web of Science ®Google Scholar
• Younas M, Psomas C, Reynes J, Corbeau P. Immune activation in the course of HIV-1 infection: Causes, phenotypes and persistence under therapy. HIV Med. 2016;17(2):89–105.10.1111/hiv.2016.17.issue-2
   PubMed Web of Science ®Google Scholar
• Blázquez D, Ramos-Amador JT, Saínz T, Mellado MJ, García-Ascaso M, De José MI, et al. Lipid and glucose alterations in perinatally-acquired HIV-infected adolescents and young adults. BMC Infect Dis. 2015;15:119.10.1186/s12879-015-0853-8
   PubMed Web of Science ®Google Scholar
• Eggena MP, Barugahare B, Okello M, Mutyala S, Jones N, Ma Y, et al. T cell activation in HIV‐seropositive Ugandans: Differential associations with viral load, CD4 + T cell depletion, and coinfection. J Infect Dis. 2005;191(5):694–701.10.1086/jid.2005.191.issue-5
   PubMed Web of Science ®Google Scholar
• Gascon RL, Narváez AB, Zhang R, Kahn JO, Hecht FM, Herndier BG, et al. Increased HLA-DR expression on peripheral blood monocytes in subsets of subjects with primary HIV infection is associated with elevated CD4 T-cell apoptosis and CD4 T-cell depletion. J Acquir Immune Defic Syndr. 2002;30(2):146–153.10.1097/00042560-200206010-00002
   PubMed Web of Science ®Google Scholar
• Piconi S, Trabattoni D, Gori A, Parisotto S, Magni C, Meraviglia P, et al. Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy. AIDS. 2010;24(13):1991–2000.10.1097/QAD.0b013e32833c93ce
   PubMed Web of Science ®Google Scholar
• Lange CG, Valdez H, Medvik K, Asaad R, Lederman MM. CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. Clin Immunol. 2002;102(2):154–161.10.1006/clim.2001.5164
   PubMed Web of Science ®Google Scholar
• Chow FC, Regan S, Feske S, Meigs JB, Grinspoon SK, Triant VA. Comparison of ischemic stroke incidence in HIV-infected and non–HIV-infected patients in a US health care system. J Acquir Immune Defic Syndr. 2012;60:351–358.10.1097/QAI.0b013e31825c7f24
   PubMed Web of Science ®Google Scholar
• Friis-Møller N, Sabin CA, Weber R, d’Arminio Monforte A, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993–2003.
   PubMed Web of Science ®Google Scholar
• Bonfanti P, Giannattasio C, Ricci E, Facchetti R, Rosella E, Franzetti M, et al. HIV and metabolic syndrome: A comparison with the general population. J Acquir Immune Defic Syndr. 2007;45:426–431.10.1097/QAI.0b013e318074ef83
   PubMed Web of Science ®Google Scholar
• Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165:1179–1184.10.1001/archinte.165.10.1179
   PubMed Web of Science ®Google Scholar
• Quin J. Diabetes and HIV. Clin Med (Lond). 2014;14(6):667–669.10.7861/clinmedicine.14-6-667
   PubMed Web of Science ®Google Scholar
• Das S. Insulin resistance and diabetes in HIV infection. Recent Pat Antiinfect Drug Discovery. 2011;6(3):260–268.10.2174/157489111796887846
   PubMedGoogle Scholar
• Hresko RC, Kraft TE, Tzekov A, Wildman SA, Hruz PW. Isoform-selective inhibition of facilitative glucose transporters: Elucidation of the molecular mechanism of HIV protease inhibitor binding. J Biol Chem. 2014;289(23):16100–16113.10.1074/jbc.M113.528430
   PubMed Web of Science ®Google Scholar
• Tien PC, Schneider MF, Cole SR, Levine AM, Cohen M, DeHovitz J, et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the women’s interagency HIV study. AIDS. 2007;21(13):1739–1745.10.1097/QAD.0b013e32827038d0
   PubMed Web of Science ®Google Scholar
• Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;351(9119):1881–1883.10.1016/S0140-6736(98)03391-1
   PubMed Web of Science ®Google Scholar
• Mohammed AE, Shenkute TY, Gebisa WC. Diabetes mellitus and risk factors in human immunodeficiency virus-infected individuals at Jimma University Specialized Hospital. Southwest Ethiopia. Diabetes Metab Syndr Obes. 2015;8:197–206.10.2147/DMSO
   PubMed Web of Science ®Google Scholar
• Nix LM, Tien PC. Metabolic syndrome, diabetes, and cardiovascular risk in HIV. Curr HIV/AIDS Rep. 2014;11(3):271–278.10.1007/s11904-014-0219-7
   PubMed Web of Science ®Google Scholar
• Grunfeld C. Dyslipidemia and its treatment in HIV infection. Top HIV Med. 2010;18(3):112–118.
   PubMedGoogle Scholar
• Araujo S, Bañón S, Machuca I, Moreno A, Pérez-Elías MJ, Casado JL. Prevalence of insulin resistance and risk of diabetes mellitus in HIV-infected patients receiving current antiretroviral drugs. Eur J Endocrinol. 2014;171(5):545–554.10.1530/EJE-14-0337
   PubMed Web of Science ®Google Scholar
• Hunt PW, Deeks SG, Rodriguez B, Valdez H, Shade SB, Abrams DI, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS. 2003;17(13):1907–1915.10.1097/00002030-200309050-00009
   PubMed Web of Science ®Google Scholar
• Jin C, Zhang F, Wu L, Xie T, Cheng Y, Tang Z, et al. Immune activation and CD127 expression on T lymphocyte subsets of a Chinese cohort of pediatric AIDS patients with different viral responses. Curr HIV Res. 2012;10(7):584–591.10.2174/157016212803305961
   PubMed Web of Science ®Google Scholar
• Rosso R, Fenoglio D, Terranova MP, Lantieri F, Risso D, Pontali E, et al. Relevance of CD38 expression on CD8 T cells to evaluate antiretroviral therapy response in HIV-1-infected youths. Scand J Immunol. 2010;71(1):45–51.10.1111/sji.2009.71.issue-1
   PubMed Web of Science ®Google Scholar
• Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997;40(11):1286–1292.10.1007/s001250050822
   PubMed Web of Science ®Google Scholar
• Wali JA, Trivedi P, Kay TW, Thomas HE. Measuring death of pancreatic beta cells in response to stress and cytotoxic T cells. Methods Mol Biol. 2015;1292:165–176.10.1007/978-1-4939-2522-3
   PubMedGoogle Scholar